BACKGROUND: In recent years, drug testing in body fluids has gained popularity for validating self-reported drug use. The storage and transportation of urine specimens is a major concern for remote areas where the facilities for performing drug abuse testing are lacking.
Introduction
O pioids top the list of "problem" drugs worldwide. [1] The use of illicit opioids like heroin along with nonmedical use of prescription opioids is a rising public health concern. This leads to increased healthcare services and deaths due to drug overdose. Among injecting drug users (IDUs), the use of opioids, especially heroin is emerging. There are an estimated 15.9 million IDUs globally.
In India, the number of IDUs is around 1.77 million. [2] Notably, almost all the IDUs in India use opioid drugs and are mostly opioid dependent. [3] Laboratory screening of substance use, especially opioids to monitor drug use is an important component of addiction treatment settings. It provides an unbiased, reproducible, and accurate method to monitor patients and offers objective support for clinical considerations. Urine is often preferred over other biological specimen, as it is readily collectible and has higher levels of drugs and metabolites in comparison to serum/blood or saliva. Drug abuse testing in patients belonging to remote areas is considered to be fraught with many logistic problems. In addition, to minimize variations, it is always advisable for the analysis to be carried out in one centralized laboratory. Transportation to a distant laboratory often involves challenges such as requirement of trained staff, sample spillage, breakage, cross contamination, and shipment in lower temperatures.
Use of dry biological specimen such as dried blood spot (DBS) or dried urine spot (DUS) is becoming popular recently, as it offers some interesting advantages over liquid samples for screening/diagnosis. [4] [5] [6] [7] [8] [9] [10] [11] [12] First, it requires a less invasive sampling method. Second, DUS provides stability even at ambient temperature. It also offers easy storage and transportation with no need for freezers or dry ice in most applications. Concerning morphine and drugs of abuse, there is a paucity of literature regarding use of dried urine spots for screening. Some recent reports are available on using dried urine spots method for morphine screening. [13] [14] [15] However, no study has reported the use of dried urine spots in an addiction treatment setting and clinical validation for morphine screening till date.
The objective of the present study was to develop a simple and cost-effective method for direct screening of morphine using urine spotted onto a filter paper and evaluating its clinical applicability.
Materials and Methods

Chemicals
All the reagents used were of analytical grade and were obtained from Merck, USA. Morphine standard was obtained morphine injection IP 15 mg/ml, Troikaa Pharmaceuticals Ltd, Gujarat, India. Whatman Filter paper 903 was obtained from GE Health Care, India.
Instrumentation and gas chromatography conditions
Screening was performed by enzyme-linked immunosorbent assay (ELISA) technique (Tecan GENios ELISA reader, Austria GmbH, Austria) using Megellan Software V1.30 (Tecan Austria, Austria).
Further confirmation of the samples was done using gas chromatograph (model 7890A, Agilent India Pvt. Ltd, USA). The gas chromatography (GC) was equipped with 7683B series Auto Sampler (split/split-less inlet, fused silica capillary column coated with HP-5 cross-linked 5% diphenyl, and 95% dimethylpolysiloxane (30 m × 0.320 i.d., 0.5 µm film thickness). The temperature gradient used was 1 min at 170°C, 10°C/min from 170°C to 270°C, and 5 min at 270°C. Nitrogen was used as a carrier gas at a flow rate of 10 ml/min. The injector temperature was 280°C. The injection volume was 2 µl for each GC run, and the split ratio was kept 1:10. The nitrogen phosphorus detector (NPD) was used with electronic pneumatic control at 300°C. System control, data acquisition, and analysis were performed with GC Chem Station G2075BA software.
Sample collection
The study was conducted at a tertiary-care addiction treatment setting of North India. The inclusion criteria included male patients fulfilling International Classification of Diseases-10 criteria [16] for harmful or dependent opioid use, recent use, within last 48 h, and willing to participate in the study. The patients who reported use of drugs other than opioid and presence of any other psychiatric illness were excluded from the study. Patient informed consent was obtained from all participants who fulfilled the inclusion criteria. After inclusion, 30 ml of urine samples were collected from each patient. Drug-free urine samples (controls) were obtained from laboratory staff volunteers. The urine samples were screened by cassette test for opiates, benzodiazepines, cannabis, and nicotine use. The study was carried out in accordance with Declaration of Helsinki, and the study protocol was approved by the institutional ethics committee. The study was completed in 1-year duration (March 2012-2013).
DUS preparation
Control urine samples with zero baseline drug level were spiked with various concentrations (100, 50, 10, and 1 µg/ml) of standard morphine. Twenty ul of morphine standards spiked in control urine sample and patient's samples were spotted onto filter paper kept on a nonabsorbent surface. The spotted samples were then allowed to dry overnight at ambient temperature.
Extraction and detection of morphine from DUS
Optimal conditions were worked out to check the maximum recovery using three different eluting solvents at different temperature (room temperature and 37°C) and time conditions (4, 24, 48, 72, and 96 h). Briefly, DUS with spiked morphine standards was punched manually using a manual puncher of diameter 3.2 mm. Three different solvents, i.e., deionized water, sodium carbonate-bicarbonate buffer (pH 9.2), and saline were tried for morphine extraction from DUS. The detection of morphine was checked with ELISA kits (Calbiotech Pvt limited, USA) onto ELISA reader as per manufacturer's guidelines. The results were given as positive or negative based on the cutoff (100 ng/ml) of ELISA kit being used.
Confirmation of the urine and dried urine spots (DUS)
were carried out as per the previously developed
Clinical validation
Urine samples were collected from 50 patients with opioid use disorders as per the inclusion criteria. All the patients were males with the mean age of 35.2 ± 9.67 years. Twenty-six percentage of the patients were unmarried (n = 13) while 74% were married (n = 37). Majority of the patients were employed (86%, n = 43) and only 14% were unemployed (n = 7). The education status was reported as illiterate 5 (10%), just literate 13 (26%), primary 10 (20%), high school 12 (24%), higher secondary 2 (4%), graduate 5 (10%), and postgraduate 3 (6%).
All the 50 samples were found to be positive for morphine in direct urine as well as filter paper-spotted urine samples by ELISA technique. Representative gas-liquid chromatography (GLC) chromatogram of morphine-spiked control urine with a retention time of 12.89 min is shown in Figure 2 . The results showed 100% concordance between filter paper-extracted urine specimens and direct urine specimens in patients' sample using GC technique.
Stability
Morphine was found to be stable in DUS samples stored at room temperatures, −20°C and 4°C [ Figure 4 ]. The concentration of morphine depicted in figure corresponds to 20 µl of urine spot extracted and estimated as per the laboratory method by extraction and derivatization before injecting to gas chromatograph. [17] 
Method validation
Percent recovery was calculated based on comparison between the standard and the extracted morphine from DUS using the following formula: × Xe % Recovery= 100 Xs Where, Xe = Mean concentration obtained from extracted standard using DUS method, and Xs = mean concentration obtained from direct standard.
For interday precision, the standards were run in triplicate for three consecutive days, and for intraday precision, the standards were repeated three times in triplicate within the same day. Both are expressed as standard deviation and coefficient of variation (% CV).
Clinical validation
The use of filter paper to screen drug use in a clinical setting was checked by collecting urine samples from opioid using patients as per the inclusion criteria. Twenty microliters of the urine samples from each patient were spotted onto filter paper and dried. The filter paper spotted urine samples (DUS), and corresponding urine samples were analyzed for morphine as per the standardized conditions.
Stability
The stability of DUS was tested by spotting the morphine spiked urine samples (1 ug/ml, 500 ng/ml) and patient's urine samples on filter paper, which were kept in sealed plastic bags with desiccants until analysis. These sealed plastic bags were stored at three different temperatures (−20°C, 4°C, and room temperature [21°C-28°C]). Estimation was carried out at different points of time, i.e., within 24 h after collection and weekly for 1 st 4 weeks and then consecutive weeks till 3 months.
Results
Optimization of DUS extraction
The extraction of morphine was carried out using three extracting solvents for different time periods. The recovery of morphine was found to be maximum (99.4%) using two punches (3.2 mm each) in 500 µL of deionized water, kept at 37°C in a water bath shaker for a period of 24 h [ Figure 1 ].
Limit of detection (LOD) for the method was found to be 100 ng/ml. The interday CV and intraday CV results are shown in Table 1 . CV=Coefficient of variation optimized conditions. The stored spotted filter paper showed no degradation at the end of 3 months.
Discussion and Conclusions
Analysis of drug use in biological fluids plays an important role in addiction treatment services. Opioids are a class of drugs that includes heroin and other legal prescription analgesics such as oxycodone, hydrocodone, codeine, morphine, and fentanyl. [18] Urine is often the most preferred specimen among biological specimens used to screen recent drug use due to its ease of collection, higher detectable concentrations of drugs, and metabolites.
Through this study, a validated method for the qualitative analysis of morphine in small volumes of urine (20 µL/spot) spotted as DUS has been developed. The extraction and screening of morphine in DUS were found comparable to the conventional urine sampling method.
In the current study, LOD was found to be fairly sensitive (100 ng\ml) for screening the recent opioid use. The current method appeared to be fairly sensitive and cost-effective in a clinical setting.
Following the new challenges encountered in the process of drugs' determination, DUS method has the potential to overcome these challenges. However, in case of morphine detection from DUS, few published reports lack the clinical validation. [13] [14] [15] Some researchers reported use of DBS to assess the stability of morphine, which complements our results of stability. [19, 20] The current study advocates the use of DUS to improve morphine stability even when stored at room temperature (up to 3 months). This is in accordance with the published report; the use of filter paper stabilizes the analyte thus increasing the chance of getting a positive result even with low concentrations for a considerable period of time after sample collection. [13] As per our knowledge, this is the first study to report the clinical validation of DUS in an addiction treatment setting to screen morphine.
This methodology was developed for the qualitative screening of morphine, and future studies with quantitative estimation with larger sample size are needed. Dried urine spot samples have been found to be a useful alternative for biological monitoring of morphine use, especially in developing countries where sample logistics could be a major problem.
Moreover, the DUS can be used as an alternative procedure in conjunction with conventional methods. It holds promise for preserving unstable drugs. It may help to avoid potential errors in analytical interpretation of results because of environmental influences. DUS has the potential to be used in field-based studies lacking laboratory facilities. Thus, the use of DUS for detecting morphine in the addiction treatment settings represents an inexpensive, rapid, precise, and simple method. These results call for further work for wider screening of participants belonging to drug using areas with limited laboratory facilities.
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